GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SeqLL Inc (OTCPK:SEQL) » Definitions » EV-to-FCF

SeqLL (SEQL) EV-to-FCF : -0.28 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is SeqLL EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SeqLL's Enterprise Value is $1.42 Mil. SeqLL's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.07 Mil. Therefore, SeqLL's EV-to-FCF for today is -0.28.

The historical rank and industry rank for SeqLL's EV-to-FCF or its related term are showing as below:

SEQL' s EV-to-FCF Range Over the Past 10 Years
Min: -102.9   Med: -0.61   Max: 0.84
Current: -0.35

During the past 7 years, the highest EV-to-FCF of SeqLL was 0.84. The lowest was -102.90. And the median was -0.61.

SEQL's EV-to-FCF is ranked worse than
100% of 99 companies
in the Medical Diagnostics & Research industry
Industry Median: 26.75 vs SEQL: -0.35

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), SeqLL's stock price is $3.10. SeqLL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-15.780. Therefore, SeqLL's PE Ratio for today is At Loss.


SeqLL EV-to-FCF Historical Data

The historical data trend for SeqLL's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SeqLL EV-to-FCF Chart

SeqLL Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - -6.81 -0.05 -0.36

SeqLL Quarterly Data
Dec18 Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.49 -0.83 -1.05 -0.36

Competitive Comparison of SeqLL's EV-to-FCF

For the Diagnostics & Research subindustry, SeqLL's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SeqLL's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SeqLL's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where SeqLL's EV-to-FCF falls into.



SeqLL EV-to-FCF Calculation

SeqLL's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.417/-5.067
=-0.28

SeqLL's current Enterprise Value is $1.42 Mil.
SeqLL's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SeqLL  (OTCPK:SEQL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

SeqLL's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.10/-15.780
=At Loss

SeqLL's share price for today is $3.10.
SeqLL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.780.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


SeqLL EV-to-FCF Related Terms

Thank you for viewing the detailed overview of SeqLL's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SeqLL (SEQL) Business Description

Traded in Other Exchanges
N/A
Address
3 Federal Street, Billerica, MA, USA, 01821
SeqLL Inc is an early commercial-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple omics fields. The company leverages its expertise with True Single Molecule Sequencing (tSMS) technology enabling researchers and clinicians to contribute advancements to scientific research and development by accelerating one's understanding of the molecular mechanisms of disease and fundamental biological processes, It enables researchers to identify and synthesize DNA or RNA strands, irrespective of abundance, in a biological sample and is capable of analyzing billions of molecules in parallel.
Executives
Douglas Patrick Miscoll director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Daniel Robert Jones officer: President, CEO 317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
David Pfeffer director 464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally officer: CHIEF FINANCIAL OFFICER 66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy officer: CFO, Secretary 166 WINN STREET, WOBURN MA 01801